Pandemic Watch
Bundibugyo ebolavirus vs Sudan ebolavirus
A factual side-by-side comparison of two ebolavirus species: Bundibugyo ebolavirus and Sudan ebolavirus. Reservoir biology, geographic distribution, clinical course, case-fatality rate, and outbreak history.
Discovery and history
Bundibugyo ebolavirus
In late 2007, clinicians at Bundibugyo Hospital in western Uganda began reporting an unexplained hemorrhagic fever. Initial laboratory testing assumed Sudan ebolavirus — the species most recently documented in the region — but PCR amplicons sequenced at the CDC produced an unexpected result: the virus shared roughly 70 percent of its genome with the other ebolaviruses, sufficiently divergent to warrant a new species designation. The pathogen was named for the district where the outbreak occurred. The outbreak ultimately produced 149 reported cases and 37 deaths.
Sudan ebolavirus
Sudan ebolavirus was first identified in 1976 in cotton-factory workers in Nzara and Maridi, southern Sudan (now South Sudan), in an outbreak that occurred almost simultaneously with the Yambuku Zaire ebolavirus outbreak across the border. The two events were initially assumed to share a virus until subsequent serological and genetic work confirmed they were distinct species. The Nzara cluster killed 151 of 284 reported cases (53 percent case-fatality) and established that the Ebola family contained multiple genetically distinct members.
Reservoir and ecology
Bundibugyo ebolavirus
As with the other ebolavirus species, the natural reservoir is strongly suspected to be fruit bats of family Pteropodidae but has not been definitively confirmed. The geographic overlap with Sudan ebolavirus across the Uganda-DRC border suggests overlapping reservoir ranges. Spillover into humans is presumed to occur through the same pathways: direct contact with infected bats or with primates and other forest mammals exposed to bat material.
Sudan ebolavirus
Like other ebolavirus species, the natural reservoir is suspected to be fruit bats of family Pteropodidae, though definitive confirmation for Sudan ebolavirus specifically has been elusive. Surveys of bat populations in Uganda and South Sudan have detected ebolavirus antibodies in several species; isolation of live virus has been rare. The spillover pathway is presumed to involve direct or indirect contact with infected bats or with primates and other forest mammals exposed to bat material — consistent with the pattern documented for Zaire ebolavirus.
Clinical course
Bundibugyo ebolavirus
Clinical course follows the broader ebolavirus pattern: an incubation of 2-21 days, a febrile prodrome with severe headache and myalgia, progression to severe gastrointestinal symptoms (vomiting, watery diarrhea), and a subset of patients developing hemorrhagic manifestations and multi-organ failure. The notable difference is the case-fatality rate: 25 to 40 percent for Bundibugyo virus across documented outbreaks, materially lower than Sudan or Zaire. The reasons are not fully understood — host genetics, viral virulence factors, and improved early supportive care have all been proposed contributors.
Sudan ebolavirus
The clinical course mirrors Zaire ebolavirus: a 2-21 day incubation, sudden onset of fever and myalgia, gastrointestinal phase with severe vomiting and diarrhea, and hemorrhagic manifestations in roughly half of severe cases. Aggressive intravenous fluid replacement is again the foundation of supportive care. Case-fatality has ranged from 41 percent (Kibaale 2012) to 71 percent (Nzara 1976), with the recent 2022 Mubende outbreak landing around 47 percent. The absence of licensed therapeutics for Sudan virus means that outcomes still depend largely on the quality and timing of supportive care.
Notable outbreaks
Bundibugyo ebolavirus
The 2007 Bundibugyo Uganda outbreak (149 cases, 37 deaths) was the discovery event and the largest until 2026. The 2012 Isiro DRC outbreak (52 cases, 25 deaths) confirmed cross-border circulation. The 2026 DRC/Uganda outbreak — currently tracked on this site's dashboard — is the largest Bundibugyo virus event recorded, with international spread to Kampala via a confirmed imported case from DRC. WHO declared the 2026 outbreak a Public Health Emergency of International Concern on May 16, 2026.
Sudan ebolavirus
The 2000 Gulu outbreak in northern Uganda (425 cases, 224 deaths) remains the largest Sudan ebolavirus event. It also shaped modern Ebola response: the WHO Global Outbreak Alert and Response Network deployed at scale for the first time, and ring infection control around Lacor Hospital became a template for subsequent outbreaks. The 2022 Mubende outbreak in central Uganda produced 164 confirmed cases and 55 deaths over four months and prompted the first ring-vaccination trial of a candidate Sudan virus vaccine. The earliest 1976 Nzara/Maridi outbreak, occurring within weeks of the parallel Zaire outbreak across the border, was the discovery event for the species.
Prevention
Bundibugyo ebolavirus
No licensed vaccine specifically against Bundibugyo virus exists. The Ervebo (rVSV-ZEBOV) vaccine targets Zaire ebolavirus only and provides no demonstrated cross-protection against Bundibugyo. Several candidate trivalent vaccines (covering Zaire, Sudan, and Bundibugyo simultaneously) are in development and have been deployed under emergency-use protocols during the 2026 PHEIC. Outside of vaccination, the response leans on the same fundamentals as other ebolavirus outbreaks: contact tracing, dedicated treatment units, safe-burial practices, and rigorous infection prevention and control in healthcare settings.
Sudan ebolavirus
No licensed vaccine or therapeutic exists specifically for Sudan ebolavirus, which is the defining gap in the current outbreak-response toolkit. The candidate vaccines cAd3-SUDV (chimpanzee adenovirus-vectored) and SVABCV-VR (chimpanzee adenovirus + MVA prime-boost) have shown safety and immunogenicity in phase I/II trials and have been deployed under ring-vaccination protocols during the 2022 Uganda Mubende outbreak and the current 2026 PHEIC. Outside of vaccination, the same infection prevention and control principles apply as for Zaire virus: rigorous PPE in healthcare settings, safe-burial protocols, contact tracing, and dedicated Ebola treatment units.
Full strain profiles: Bundibugyo ebolavirus · Sudan ebolavirus. For the broader disease guide, see ebola.
